Soligenix (SNGX) Competitors $2.74 -0.19 (-6.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.77 +0.03 (+1.09%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. MBRX, HOTH, EDSA, NXTC, CARM, NEUP, MTEX, ALLR, LPTX, and NERVShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Moleculin Biotech (MBRX), Hoth Therapeutics (HOTH), Edesa Biotech (EDSA), NextCure (NXTC), Carisma Therapeutics (CARM), Neuphoria Therapeutics (NEUP), Mannatech (MTEX), Allarity Therapeutics (ALLR), Leap Therapeutics (LPTX), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Moleculin Biotech Hoth Therapeutics Edesa Biotech NextCure Carisma Therapeutics Neuphoria Therapeutics Mannatech Allarity Therapeutics Leap Therapeutics Minerva Neurosciences Soligenix (NASDAQ:SNGX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment. Does the media prefer SNGX or MBRX? In the previous week, Soligenix had 3 more articles in the media than Moleculin Biotech. MarketBeat recorded 7 mentions for Soligenix and 4 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.36 beat Soligenix's score of 0.15 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in SNGX or MBRX? 3.6% of Soligenix shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 2.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate SNGX or MBRX? Soligenix currently has a consensus target price of $6.00, indicating a potential upside of 118.98%. Moleculin Biotech has a consensus target price of $4.00, indicating a potential upside of 501.41%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, SNGX or MBRX? Soligenix has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Which has stronger earnings and valuation, SNGX or MBRX? Soligenix has higher earnings, but lower revenue than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoligenix-$117.03K-76.42-$8.27M-$4.29-0.64Moleculin BiotechN/AN/A-$21.76MN/AN/A Is SNGX or MBRX more profitable? Soligenix's return on equity of -223.89% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets SoligenixN/A -223.89% -103.50% Moleculin Biotech N/A -278.80%-100.11% SummaryMoleculin Biotech beats Soligenix on 6 of the 11 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.56M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.6417.6228.6723.80Price / Sales-76.42179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book1.678.508.275.55Net Income-$8.27M-$55.06M$3.24B$259.03M7 Day Performance107.58%-3.98%-3.69%-4.59%1 Month Performance117.46%9.59%4.33%4.46%1 Year Performance-30.98%6.72%25.95%18.03% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix2.0564 of 5 stars$2.74-6.5%$6.00+119.0%-37.6%$9.56M-$117.03K-0.6420News CoverageUpcoming EarningsShort Interest ↑Gap DownMBRXMoleculin Biotech2.8807 of 5 stars$0.55-2.9%$4.00+626.9%-70.7%$17.13MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap DownHOTHHoth Therapeutics2.8671 of 5 stars$1.31+2.3%$4.00+205.3%+89.1%$16.91MN/A-1.154News CoverageUpcoming EarningsAnalyst ForecastEDSAEdesa Biotech1.7211 of 5 stars$2.33-2.1%$5.00+114.6%-59.1%$16.71MN/A-1.4720Positive NewsUpcoming EarningsNXTCNextCure4.5767 of 5 stars$5.54-10.2%$33.00+495.7%-74.7%$16.51MN/A-0.2690News CoverageUpcoming EarningsGap DownCARMCarisma Therapeutics2.2058 of 5 stars$0.37-5.9%$1.93+427.0%-69.8%$16.21M$19.63M-0.2320Upcoming EarningsGap DownNEUPNeuphoria Therapeutics1.1823 of 5 stars$8.69+2.2%$21.00+141.7%N/A$15.98M$10K0.00N/AMTEXMannatechN/A$8.05-3.4%N/A+19.2%$15.84M$117.87M-80.45250Gap DownALLRAllarity Therapeutics2.7332 of 5 stars$1.12+9.8%$9.00+703.6%-80.9%$15.38MN/A0.0010Upcoming EarningsAnalyst DowngradeAnalyst RevisionGap DownHigh Trading VolumeLPTXLeap Therapeutics1.9014 of 5 stars$0.34-5.6%$3.38+893.8%-85.6%$14.91MN/A-0.2040Gap DownNERVMinerva Neurosciences2.7359 of 5 stars$2.10-1.4%$5.00+138.1%-35.8%$14.90MN/A2.569Upcoming Earnings Related Companies and Tools Related Companies Moleculin Biotech Competitors Hoth Therapeutics Competitors Edesa Biotech Competitors NextCure Competitors Carisma Therapeutics Competitors Neuphoria Therapeutics Competitors Mannatech Competitors Allarity Therapeutics Competitors Leap Therapeutics Competitors Minerva Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNGX Stock Alerts